Wegovy是一种有效的体重损失注射,由于成本高,限制了数百万人的获得服务的机会,因此受到国民保健制度的限制。 Wegovy, an effective weight-loss injection, is restricted by the NHS due to high costs, limiting access for millions.

Wegovy, 体重损失注射, 帮助62岁的Ray在五个月中损失了14公斤, Wegovy, a weight-loss injection, helped 62-year-old Ray lose 14kg in five months, but the NHS restricts access due to high costs. 在英格兰的340万合格病人中,只有一小部分人可以得到这种药物,每名病人最多可服用两年。 Only a fraction of the 3.4 million eligible patients in England can receive the drug, limited to two years per patient. 向所有符合条件的个人引进这种药物每年将花费100亿英镑,有可能使国民保健制度破产。 Introducing the drug to all eligible individuals would cost £10 billion annually, potentially bankrupting the NHS. 第二项药物,Mounjaro,经国家营养与健康研究所批准,面临类似的推广挑战,以避免保健服务负担过重。 A second drug, Mounjaro, approved by NICE, faces similar rollout challenges to avoid overwhelming health services.